Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person When bound to its endogenous ligand histamine, the histamine...

Class:IdSummation:9692835
_displayNameWhen bound to its endogenous ligand histamine, the histamine...
_timestamp2020-06-26 12:46:43
created[InstanceEdit:9692827] Jassal, Bijay, 2020-06-26
literatureReference[LiteratureReference:390882] International Union of Pharmacology. XIII. Classification of histamine receptors
[LiteratureReference:9692836] Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease
[LiteratureReference:9692821] Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases
[LiteratureReference:9692828] Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome
[LiteratureReference:9692839] Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease
textWhen bound to its endogenous ligand histamine, the histamine H2 receptor (HRH2) mediates mediates gastric acid secretion, gastrointestinal motility and intestinal secretion. HRH2 is also thought to be involved in regulating cell growth and differentiation (Panula et al. 2015). The HRH2 antagonists cimetidine (Black et al. 1972, Ganellin 1981), ranitidine (Brogden et al. 1982), nizatidine (Price & Brogden 1988) and famotidine (Campoli-Richards & Clissold 1986) are well established treatments (Baker et al. 2008) for patients presenting with dyspepsia, gastric or duodenal ulcers, or gastroesophageal reflux disease (Sigterman et al. 2013).
(summation)[Reaction:9692738] HRH2 binds HRH2 antagonists [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by When bound to its endogenous ligand histamine, the histamine... (9692835)
Follow Reactome